Verve Therapeutics amends bylaws to align with universal proxy rules

Verve Therapeutics, Inc.

Board approved Second Amended and Restated Bylaws effective February 14, 2023.
Eliminates requirement to provide stockholder list during meetings; adds adjournment for technical failures.
Enhances nomination procedures: requires disclosure and 67% voting power solicitation under Rule 14a-19.
Non-compliant nominations will be disregarded; proxies or votes for such nominees not counted.
Includes technical, conforming, and clarifying changes.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Verve Therapeutics, Inc.: Amendment and restatement of bylaws eliminating stockholder list requirement during meetings, addressing remote meeting adjournment due to technical failure, and revising procedural mechanics for stockholder nominations and proposals under universal proxy rules (effective 2023-02-14).

Change: bylaw amendment
Effective: 2023-02-14

Exact text from the filing

On February 14, 2023, the board of directors (the “Board”) of Verve Therapeutics, Inc. (the “Company”) approved an amendment and restatement of the Company’s Amended and Restated Bylaws (as so amended and restated, the “Second Amended and Restated Bylaws”), effective immediately.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001193125-23-041486

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.